Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Commercial Sponsor
BeiGene Australia Pty Ltd
Summary
This is a non-randomised trial, in which patients will be allocated to one of five cohorts according to their tumor type and prior anti-programmed cell death protein-1 (PD-1)/PD-L1 antibody treatment. Cohort allocation is as described. Cohort A: Patients with anti-PD-1/PD-L1 antibody refractory/resistant metastatic, non-squamous NSCLC
Cohort B: Patients with anti-PD-1/PD-L1 antibody naïve metastatic, non-squamous NSCLC. Cohort C: Patients with anti-PD-1/PD-L1 antibody refractory/resistant metastatic or advanced RCC. Cohort D (China-only): Patients with metastatic or advanced RCC without prior systemic therapy. Cohort E: Patients with anti-PD-1/PD-L1 antibody naïve recurrent and platinum resistant Epithelial OC.All cohorts will receive sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks.